Innate Pharma
IPHA
13 hedge funds and large institutions have $2.58M invested in Innate Pharma in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 13 → 13 (0)
0% more ownership
Funds ownership: 1.19% → 1.2% (+0%)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
19% less capital invested
Capital invested by funds: $3.2M → $2.58M (-$623K)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Optiver Holding
Amsterdam,
Netherlands
|
+$416K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$8.6K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7.57K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$5.76K |
| 5 |
Morgan Stanley
New York
|
+$4.78K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AA
ALPS Advisors
Denver,
Colorado
|
-$282K |
| 2 |
Jane Street
New York
|
-$127K |
| 3 |
Two Sigma Investments
New York
|
-$31.4K |
| 4 |
Millennium Management
New York
|
-$24K |
| 5 |
BlackRock
New York
|
-$20.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
BlackRock
New York
| $1.34M | -$20.8K | -7,133 | -1% |
|
|
2
Optiver Holding
Amsterdam,
Netherlands
| $491K | +$416K | +142,970 | +367% |
|
3
Bank of America
Charlotte,
North Carolina
| $473K | +$131 | +45 | +0% |
|
|
4
Morgan Stanley
New York
| $126K | +$4.78K | +1,644 | +4% |
|
|
5
Two Sigma Investments
New York
| $68K | -$31.4K | -10,800 | -30% |
|
|
6
Millennium Management
New York
| $46K | -$24K | -8,259 | -33% |
|
|
7
UBS Group
Zurich,
Switzerland
| $8K | +$8.6K | +2,956 | New |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $7K | +$7.57K | +2,600 | New |
|
9
Barclays
London,
United Kingdom
| $6K | -$3.58K | -1,232 | -36% |
|
|
CS
10
Credit Suisse
Zurich,
Switzerland
| $5K | +$5.76K | +1,981 | New |
|
11
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| $2K | – | – | – |
|
|
SPIA
12
Steward Partners Investment Advisory
New York
| $1K | – | – | – |
|
|
AA
13
ALPS Advisors
Denver,
Colorado
| – | -$282K | -83,966 | Closed |
|
|
14
Jane Street
New York
| – | -$127K | -37,736 | Closed |
|
15
Osaic Holdings
Scottsdale,
Arizona
| – | -$3K | -1,000 | Closed |
|
IPHA Hedge Fund Activity: Q2 2022 in Review
13 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Innate Pharma (IPHA) for Q2 2022, worth a combined $2.58M — down 19% from $3.2M a quarter earlier.
Fund positioning in IPHA was balanced in Q2 2022: 3 funds opened new positions, 3 closed out, 3 added to existing stakes and 4 trimmed.
The largest buyer was Optiver Holding, adding an estimated $416K. The largest seller was ALPS Advisors, exiting entirely with an estimated $282K sold.
- 13 institutional investors held Innate Pharma (IPHA) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $2.58M of Innate Pharma stock for Q2 2022, down 19% quarter-over-quarter.
- 3 funds opened new Innate Pharma positions in Q2 2022 and 3 closed out, a net change of 0 holders.
- The largest Innate Pharma buyer in Q2 2022 was Optiver Holding, an estimated $416K added.
- The largest Innate Pharma seller in Q2 2022 was ALPS Advisors, an estimated $282K sold.
Based on aggregated 13F filings for Q2 2022.